<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Manifestations of multiple sclerosis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Manifestations of multiple sclerosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Manifestations of multiple sclerosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Olek, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ram N Narayan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elliot M Frohman, MD, PhD, FANA, FAAN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Teresa C Frohman, MSPA, PA-C, FANA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diseases that affect central nervous system myelin can be categorized as demyelinating (acquired, inflammatory) and dysmyelinating (abnormal formation of myelin, usually genetic basis)  (<a class="graphic graphic_table graphicRef80553" href="/z/d/graphic/80553.html" rel="external">table 1</a>). The most common immune-mediated inflammatory demyelinating disease of the central nervous system is multiple sclerosis (MS).</p><p>The clinical manifestations of MS will be reviewed here. Other aspects of MS are discussed separately:</p><p> <a class="medical medical_review" href="/z/d/html/96016.html" rel="external">Pathogenesis and epidemiology of multiple sclerosis</a></p><p> <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">Clinical presentation, course, and prognosis of multiple sclerosis in adults</a></p><p> <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis</a></p><p> <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">Evaluation and diagnosis of multiple sclerosis in adults</a></p><p> <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">Symptom management of multiple sclerosis in adults</a></p><p> <a class="medical medical_review" href="/z/d/html/1698.html" rel="external">Treatment of acute exacerbations of multiple sclerosis in adults</a></p><p> <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults</a></p><p> <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">Treatment of secondary progressive multiple sclerosis in adults</a></p><p class="headingAnchor" id="H793790662"><span class="h1">PRESENTATION</span><span class="headingEndMark"> — </span>Most patients with MS have relapsing-remitting disease, which typically presents in a young adult with a clinically isolated syndrome suggestive of MS such as optic neuritis, long tract symptoms/signs (eg, numbness, paresthesia, or weakness), a brainstem syndrome (eg, internuclear ophthalmoplegia), or a spinal cord syndrome (eg, transverse myelitis). Approximately 5 to 10 percent of adult patients have the primary progressive form of MS, which presents with gradual accumulation of disability from the onset, without superimposed acute relapses. The most common clinical presentation of primary progressive MS is a spinal cord syndrome with spastic paraparesis and no clear sensory level [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults", section on 'Disease onset and pattern'</a> and  <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"</a>.)</p><p>A relapse (also called an attack or exacerbation, or a clinically isolated syndrome when it is the first episode) is defined as the acute or subacute onset of a monophasic clinical episode with patient-reported symptoms and objective findings typical of MS, reflecting a focal or multifocal inflammatory demyelinating event in the central nervous system, with a duration of at least 24 hours, in the absence of fever or infection [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL SYMPTOMS AND SIGNS</span><span class="headingEndMark"> — </span>There are no clinical manifestations that are unique to MS, but some are highly characteristic of the disease  (<a class="graphic graphic_table graphicRef63940" href="/z/d/graphic/63940.html" rel="external">table 2</a>). Common symptoms and signs of MS  (<a class="graphic graphic_table graphicRef61789" href="/z/d/graphic/61789.html" rel="external">table 3</a>) include sensory symptoms in the limbs or one side of the face, visual loss, acute or subacute motor weakness, diplopia, gait disturbance and balance problems, Lhermitte sign (electric shock-like sensations that run down the back and/or limbs upon flexion of the neck), vertigo, bladder problems, limb ataxia, acute transverse myelitis, and pain [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2851516956"><span class="h2">Bowel and bladder dysfunction</span><span class="headingEndMark"> — </span>Approximately 50 percent of patients with MS report bowel dysfunction and up to 75 percent report bladder dysfunction [<a href="#rid4">4</a>]. The extent of sphincter and sexual dysfunction often parallels the degree of motor impairment in the lower extremities. The most frequent urinary complaint is urgency, which is usually the result of uninhibited detrusor contraction due to a suprasegmental lesion. </p><p>Urinary incontinence becomes more common as the disease progresses. (See  <a class="medical medical_review" href="/z/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease", section on 'Urinary complications'</a>.)</p><p>Neurogenic bladder dysfunction in MS can be categorized according to the underlying pathophysiologic mechanisms, which generally lead to failure of the bladder to empty or store urine [<a href="#rid5">5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Detrusor overactivity (ie, overactive bladder), leading to failure of the bladder to store urine. The resulting symptoms include urgency, frequency, and urge incontinence. Detrusor overactivity is the most common urologic abnormality affecting patients with MS, and is typically caused by cortical demyelinating lesions that impair the detrusor reflex at the level of the frontal cortex.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Detrusor sphincter dyssynergia, the term used to describe detrusor contraction without urethral sphincter relaxation, leading to functional bladder outlet obstruction and failure to empty, typically caused by lesions involving the pontine micturition center or spinal cord lesions above the sacral parasympathetic centers. Associated symptoms include hesitancy, interrupted stream, and incomplete voiding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inefficient bladder contractility, leading to failure of the bladder to empty, and attributed to lesions spinal cord lesions that disrupt coordination with the pontine micturition center. Related symptoms include incomplete emptying, residual urine, and frequency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal sensation and bladder hypoactivity due to involvement of sacral segments of the spinal cord, leading to failure to empty (ie, an atonic dilated bladder that empties by overflow); this condition results from loss of perception of bladder fullness, and it is usually associated with urethral, anal, and genital hypesthesia, and sensory deficits in the sacral dermatomes. Symptoms include urinary retention, interrupted micturition, and incomplete bladder emptying.</p><p></p><p>While these can exist in isolation, many patients with MS have several concurrent types of bladder dysfunction [<a href="#rid5">5</a>].</p><p>Neurogenic bowel dysfunction in patients with MS can be divided into disorders of storage and elimination [<a href="#rid7">7</a>]. These problems may be a result of both upper and lower motor neuron impairment. Constipation, poor evacuation, and incontinence are the most common bowel disorders associated with MS, in that order. One study of 221 patients with MS found that 54 percent had constipation while 29 percent experienced fecal incontinence [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H2500759987"><span class="h2">Cognitive impairment</span><span class="headingEndMark"> — </span>Frank dementia is an uncommon feature of MS [<a href="#rid9">9</a>], occurring in fewer than 5 percent of patients. It is usually only encountered in severely affected individuals. However, when evaluated with neuropsychological tests, up to 70 percent of patients have some cognitive impairment [<a href="#rid10">10</a>]. The prevalence of cortical syndromes such as aphasia, apraxia, and agnosia is low.</p><p>Cognitive impairment may be common even at the onset of MS [<a href="#rid11">11,12</a>]. The most frequent abnormalities are in attention, executive functioning, abstract conceptualization, short term memory, word recall, and speed of information processing [<a href="#rid12">12,13</a>]. Different disease courses may have different cognitive profiles. As an example, there is evidence that patients with relapsing-remitting MS generally have better cognitive performance than patients with progressive types of MS [<a href="#rid14">14,15</a>]. Of note, subtle alterations in cognitive functioning may remain unidentified during routine office practice, notwithstanding the application of rapid assessment tools such as the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MOCA) tools. (See  <a class="medical medical_review" href="/z/d/html/5083.html" rel="external">"Evaluation of cognitive impairment and dementia", section on 'Cognitive testing'</a>.)</p><p>The degree of cognitive decline in patients with MS correlates with the severity of cerebral pathology and lesion burden on MRI [<a href="#rid12">12,16-19</a>], including the persistence of T1 black holes (signifying loss of tissue architecture), and atrophy of the corpus callosum and thalamus [<a href="#rid16">16-24</a>]. Cortical atrophy as measured by MRI  (<a class="graphic graphic_diagnosticimage graphicRef58083" href="/z/d/graphic/58083.html" rel="external">image 1</a>) correlates with cognitive changes, suggesting that gray as well as white matter atrophy may contribute to the cognitive decline in patients with MS [<a href="#rid20">20-24</a>].</p><p>Depression frequently has a negative impact on cognition, particularly on memory, attention, and concentration (see <a class="local">'Depression'</a> below). Depression, lack of social support, and the presence of cognitive impairment have been shown to correlate with one another, independent of level of physical disability [<a href="#rid25">25</a>]. Depression is also correlated with use of less effective coping styles [<a href="#rid26">26</a>]. These relationships are likely quite complex and interactive.</p><p>The ability of severe clinical depression to reduce performance on neuropsychological measures is well established in healthy controls and in patients with known risk factors for cognitive dysfunction, such as those with traumatic brain injury. In patients with MS, a number of cognitive domains related to executive functioning may be especially vulnerable to depression. These domains include working memory, planning ability, information processing speed, and nonspeeded central executive skill [<a href="#rid27">27-30</a>]. Thus, depression likely contributes to cognitive dysfunction in patients with MS, which in turn leads to impaired problem solving and poor coping in real world situations, where people have to make flexible and instantaneous coping choices.</p><p>Acute cerebral lesions occasionally manifest as a confusional state associated with progressive focal paralysis. These findings can be mistakenly attributed to a tumor [<a href="#rid31">31</a>].</p><p>The management of cognitive impairment in MS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Cognitive impairment'</a>.)</p><p class="headingAnchor" id="H3045694797"><span class="h2">Depression</span><span class="headingEndMark"> — </span>Cross-sectional studies have shown some degree of affective disturbance in up to two-thirds of patients with MS [<a href="#rid32">32</a>]. </p><p>Depression may be more common in patients with MS than in others with chronic medical conditions [<a href="#rid26">26,33</a>]. In addition, the risk of suicide in patients with MS may be increased in comparison with the general population, as shown in most [<a href="#rid34">34-37</a>] but not all [<a href="#rid38">38</a>] studies. The median life expectancy in patients with MS is reduced by about 5 to 10 years compared with that of the general population [<a href="#rid39">39,40</a>]; suicide probably has only a small effect on this diminution.</p><p>Some of the numerous medical and psychiatric comorbidities that contribute to depression in MS are pain, anxiety, fatigue, substance abuse, and cognitive impairment; conversely, depression appears to have a major deleterious impact on cognitive function in patients with MS. (See <a class="local">'Cognitive impairment'</a> above.)</p><p>Early trials suggested that treatment with an interferon beta may contribute to the development or unmasking of depression, but subsequent studies have not found such an association [<a href="#rid41">41-44</a>].</p><p>The management of depression in patients with MS is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Depression'</a>.)</p><p class="headingAnchor" id="H3767484314"><span class="h2">Epilepsy</span><span class="headingEndMark"> — </span>Epilepsy is more common in patients with MS than in the general population, occurring in 2 to 3 percent of patients [<a href="#rid45">45</a>]. Approximately two-thirds of seizures in patients with MS are primary or secondary generalized seizures, while the remaining one-third are partial. Simple partial seizures are about twice as common as complex partial seizures in patients with MS. This differs from the general population, where complex partial seizures are more frequent than simple partial [<a href="#rid45">45</a>].</p><p>Seizures associated with MS are generally benign and transient and respond well to antiseizure medication therapy or require no therapy. This issue is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Seizures'</a>.)</p><p class="headingAnchor" id="H2912572256"><span class="h2">Eye movement abnormalities</span><span class="headingEndMark"> — </span>A host of efferent visual disturbances can occur as manifestations of MS, including the following [<a href="#rid46">46,47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities of voluntary gaze (very common)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Internuclear ophthalmoplegia (see <a class="local">'Internuclear ophthalmoparesis'</a> below) </p><p class="bulletIndent2"><span class="glyph">•</span>Ocular dysmetria and gaze impersistence</p><p class="bulletIndent2"><span class="glyph">•</span>Horizontal gaze palsy</p><p class="bulletIndent2"><span class="glyph">•</span>One-and-a-half syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Dorsal midbrain syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Skew deviation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nystagmus (very common)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Horizontal</p><p class="bulletIndent2"><span class="glyph">•</span>Vertical</p><p class="bulletIndent2"><span class="glyph">•</span>Pendular (see <a class="local">'Pendular nystagmus'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Periodic alternating</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities of slow phase eye movements (common)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Disordered smooth pursuit</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paroxysmal disorders of eye movements (less common)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ocular flutter</p><p class="bulletIndent2"><span class="glyph">•</span>Square wave jerks</p><p class="bulletIndent2"><span class="glyph">•</span>Opsoclonus</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolated ocular motor nerve palsies (uncommon)</p><p></p><p>These eye movement abnormalities can result in variable degrees of diplopia or oscillopsia (ie, the illusion of environmental movement) [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/5238.html" rel="external">"Overview of diplopia"</a> and  <a class="medical medical_review" href="/z/d/html/5109.html" rel="external">"Overview of nystagmus"</a> and  <a class="medical medical_review" href="/z/d/html/5108.html" rel="external">"Jerk nystagmus"</a> and  <a class="medical medical_review" href="/z/d/html/5111.html" rel="external">"Pendular nystagmus"</a>.)</p><p class="headingAnchor" id="H407498140"><span class="h3">Internuclear ophthalmoparesis</span><span class="headingEndMark"> — </span>Internuclear ophthalmoparesis (INO) refers to abnormal horizontal ocular movements with lost or delayed adduction and horizontal nystagmus of the abducting eye. INO is caused by a lesion of the medial longitudinal fasciculus in the brainstem on the side of diminished adduction. Convergence is typically preserved. When present bilaterally, it is usually coupled with vertical nystagmus on upward gaze. A bilateral INO is most suggestive of MS but can also be observed with other intraaxial brainstem lesions, including brainstem glioma, vascular lesions, Arnold-Chiari malformations, and Wernicke encephalopathy. (See  <a class="medical medical_review" href="/z/d/html/5239.html" rel="external">"Internuclear ophthalmoparesis"</a>.)</p><p class="headingAnchor" id="H3253447254"><span class="h3">Pendular nystagmus</span><span class="headingEndMark"> — </span>Approximately 2 to 4 percent of patients with MS develop acquired pendular nystagmus [<a href="#rid48">48,49</a>]; most patients with this form of nystagmus have MS [<a href="#rid50">50</a>]. It is seldom a presenting sign of MS, more typically developing later in the course of disease and persisting indefinitely, resolving in only 5 percent. (See  <a class="medical medical_review" href="/z/d/html/5111.html" rel="external">"Pendular nystagmus", section on 'Acquired pendular nystagmus'</a>.)</p><p>Acquired pendular nystagmus is characterized by rapid, small-amplitude pendular oscillations of the eyes in the primary position resembling quivering jelly. Patients frequently complain of oscillopsia, which impairs visual performance. Marked impairment of visual acuity may also be present, due in part to blurring from constant eye motion and perhaps also to concurrent optic neuropathy [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H2099988758"><span class="h2">Fatigue</span><span class="headingEndMark"> — </span>Fatigue is a characteristic finding in MS, usually described as physical exhaustion that is unrelated to the amount of activity performed. The impact of fatigue is suggested by the findings of a survey of 223 patients with MS; fatigue was the most common currently experienced symptom (86 percent), and it was rated as the worst symptom causing difficulty or distress by 65 percent, higher than any other symptom [<a href="#rid3">3</a>]. Fatigue interferes with daily activities.</p><p>Primary MS-related fatigue typically occurs daily and worsens as the day goes on. Many patients complain of feeling exhausted on waking, even if they have slept soundly. Fatigue can also occur during the day but may be partially or completely relieved by rest. It is often aggravated by heat and humidity. This is considered to be due to slowing of neuronal conduction with increased body temperature (see <a class="local">'Heat sensitivity'</a> below). In addition, there appears to be a correlation between fatigue and disrupted sleep in MS patients [<a href="#rid51">51,52</a>].</p><p>Fatigue is often seen in association with an acute MS attack and may precede the focal neurologic features of the attack and persist long after the attack has subsided [<a href="#rid52">52</a>]. In addition, fatigue has been correlated with measures of cerebral axonal injury, implying a central nervous system component to the development of fatigue [<a href="#rid53">53</a>]. However, there is a poor correlation between fatigue and the overall severity of MS or with the presence of any particular symptom or sign of MS.</p><p>A number of secondary problems associated with MS may also cause or worsen fatigue. Many of these are treatable and include:</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep disturbances secondary to muscle spasms or bladder problems</p><p class="bulletIndent1"><span class="glyph">●</span>Depression</p><p class="bulletIndent1"><span class="glyph">●</span>Mobility limitations</p><p class="bulletIndent1"><span class="glyph">●</span>Infections</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid disorders and chronic thyroid infections</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep apnea; central or obstructive</p><p class="bulletIndent1"><span class="glyph">●</span>Restless legs syndrome [<a href="#rid52">52</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Medications, including antihistamines, anti-inflammatory drugs, antihypertensive medications, heart medications, muscle relaxants, sedative-hypnotics (including antihistamines such as <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>) [<a href="#rid54">54</a>], and diabetes therapy</p><p></p><p>The treatment of fatigue associated with MS is discussed in elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Fatigue'</a>.)</p><p class="headingAnchor" id="H392245186"><span class="h2">Heat sensitivity</span><span class="headingEndMark"> — </span>Heat sensitivity (Uhthoff phenomenon) is a well-known occurrence in MS; small increases in the body temperature can temporarily worsen current or preexisting signs and symptoms [<a href="#rid55">55,56</a>]. Transient increases in the frequency or severity of clinical signs and symptoms as a result of elevated body temperature are experienced by 60 to 80 percent of individuals with MS [<a href="#rid57">57</a>]. The temporary worsening of neurologic signs and symptoms of MS in response to heat exposure can diminish physical and cognitive function of affected patients with MS, and impede activities of daily living and other functional capabilities [<a href="#rid57">57,58</a>].</p><p>This phenomenon is presumably the result of conduction block developing in central pathways as the body temperature increases [<a href="#rid59">59</a>]. Normally, the nerve conduction safety factor decreases with increasing temperature until a point is reached at which conduction block occurs; this point of conduction block is reached at a much lower temperature in demyelinated nerves [<a href="#rid56">56</a>]. </p><p class="headingAnchor" id="H3269342012"><span class="h2">Motor symptoms</span><span class="headingEndMark"> — </span>In patients with MS, paraparesis or paraplegia are more common than isolated upper extremity weakness due to the frequent occurrence of lesions in the descending motor tracts of the spinal cord. Physical findings include spasticity, usually more marked in the legs than in the arms (see <a class="local">'Spasticity'</a> below). The deep tendon reflexes are exaggerated, sustained clonus may be elicited, and extensor plantar responses are observed. All of these manifestations are commonly asymmetrical.</p><p>Occasionally, deep tendon reflexes are decreased due to lesions interrupting the reflex arc at a segmental level, and an inverted triceps reflex may be observed. In it, the triceps contraction is lost and the efferent component is represented by a contraction of the biceps muscle. The Achilles reflex can be absent due to lesions of the sacral segments of the spinal cord, with or without concomitant sphincter and sexual problems. Occasionally, reduced reflexes reflect hypotonia resulting from cerebellar pathway lesions.</p><p>Amyotrophy can occur and is usually of the disuse type, most frequently affecting the small muscles of the hand. Less commonly, lesions of the motor root exit zones cause muscle denervation due to axon loss. Secondary entrapment neuropathies are also a cause of muscle atrophy in MS.</p><p>Brainstem-related symptoms like dysphagia, dysarthria, and respiratory dysfunction (particularly poor cough and inability to clear secretions) can occur in advanced MS disease.</p><p class="headingAnchor" id="H2291163918"><span class="h3">Incoordination</span><span class="headingEndMark"> — </span>Gait imbalance, difficulty in performing coordinated actions with the arms and hands, and slurred speech often occur as a result of impairment of cerebellar pathways. Cerebellar signs are usually mixed with pyramidal (corticospinal) tract signs.</p><p>Physical examination typically reveals dysmetria, decomposition of complex movements, and hypotonia, most often observed in the upper extremities. An intention tremor may be noted in the limbs and in the head; tremor affects 45 percent of patients with MS, with severe tremor in 6 percent [<a href="#rid60">60</a>].<strong> </strong>Walking is impaired by truncal ataxia. Ocular findings of nystagmus, ocular dysmetria, and failure of fixation suppression (square wave jerks) suggest cerebellar or cerebello-vestibular connection dysfunction. Speech can be scanning or explosive in character. In severe cases there is complete astasia (inability to stand), inability to use the arms due to a violent intention tremor, and virtually incomprehensible speech.</p><p class="headingAnchor" id="H1992905453"><span class="h3">Spasticity</span><span class="headingEndMark"> — </span>Spasticity affects a majority of patients with MS. In a registry of over 20,000 patients with MS who reported symptoms by completing a questionnaire, the degree and frequency of spasticity were as follows [<a href="#rid61">61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>No spasticity, 16 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Minimal (does not interfere with activities), 31 percent </p><p class="bulletIndent1"><span class="glyph">●</span>Mild (occasionally affects activities), 19 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate (frequently affects activities), 17 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Severe (need to modify daily activities), 13 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Total (prevents daily activities), 4 percent</p><p></p><p>The increased muscle tone underlying spasticity is due to an upper motor neuron lesion caused by demyelination of the corticospinal system, which leads to release of inhibition on the local spinal neurons and sensory afferent pathways. Other proposed mechanisms of spasticity include prolonged motor neuron discharge, connective tissue changes, and abnormal muscle coactivation [<a href="#rid62">62,63</a>].</p><p>Some experts recognize two types of spasticity:</p><p class="bulletIndent1"><span class="glyph">●</span>Tonic spasticity, characterized by resistance to movement that is rate dependent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Phasic spasticity, which manifests as involuntary jerks and spasms that principally affect the limbs and are more pronounced at night when attempting to sleep</p><p></p><p>The legs are most commonly affected by both forms of spasticity, but alternate patterns are recognized. Other affected regions include the cervical neck muscles, the pelvic floor, fingers and toes, and the axial paravertebral muscles.</p><p>When spasticity is severe, extensor spasms of the legs and sometimes the trunk may be provoked by active or passive attempts to rise from a bed or wheelchair.</p><p>In clinical practice, spasticity is graded by using the Modified Ashworth scale, as shown in the table  (<a class="graphic graphic_table graphicRef93413" href="/z/d/graphic/93413.html" rel="external">table 4</a>). </p><p class="headingAnchor" id="H3613155376"><span class="h2">Pain</span><span class="headingEndMark"> — </span>Pain is a common symptom in patients with MS [<a href="#rid64">64,65</a>]. A systematic review and meta-analysis of pain in adults with MS found 28 studies that met inclusion criteria with over 7000 subjects [<a href="#rid65">65</a>]. The pooled overall prevalence of pain was 63 percent. Types of pain and their prevalence in this population were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Headache in 43 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Neuropathic extremity pain in 26 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Back pain in 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Lhermitte sign in 16 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Painful spasms in 15 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Trigeminal neuralgia in 4 percent</p><p></p><p>Pain associated with MS can arise from neurogenic and non-neurogenic sources [<a href="#rid66">66</a>]. Neurogenic pain includes paroxysmal pain, persistent pain (eg, burning or ice-cold dysesthesias of the feet, hands, limbs, and trunk), and episodic neuropathic pain. Musculoskeletal and soft tissue pain may be caused by paralysis, immobility, or spasticity.</p><p>A phenomenon referred to as the "MS hug" or as the "Anaconda sign" is variably attributed to neuropathic pain or to spasticity of the thoracic and abdominal muscles; it consists of gripping, squeezing, and constricting sensations, and is often uncomfortable or painful. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Pain'</a>.)</p><p class="headingAnchor" id="H4106829378"><span class="h2">Paroxysmal symptoms</span><span class="headingEndMark"> — </span>Paroxysmal attacks of motor or sensory phenomena can occur with demyelinating lesions. These symptoms are characterized by brief, almost stereotypic, events occurring frequently and often triggered by movement or sensory stimuli [<a href="#rid67">67</a>]. They are likely caused by ephaptic transmission of nerve impulses at sites of previous disease activity. Although troublesome to the patient, these symptoms do not indicate a true exacerbation of MS or cause a loss of myelin in the central nervous system.</p><p>Within the brainstem, lesions may cause paroxysmal diplopia, facial paresthesia, trigeminal neuralgia, ataxia, and dysarthria. Motor system involvement results in painful tonic spasms of muscles of one or two (homolateral) limbs, trunk, and occasionally the face, but these only rarely occur in all four limbs or the trunk. These paroxysmal attacks typically respond to low doses of <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> and frequently remit after several weeks to months, usually without recurrence. These symptoms and their management are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Paroxysmal motor and sensory symptoms'</a>.)</p><p class="headingAnchor" id="H3348420977"><span class="h3">Lhermitte sign</span><span class="headingEndMark"> — </span>The Lhermitte sign is a transient sensory symptom described as an electric shock radiating down the spine or into the limbs most often after flexion of the neck [<a href="#rid68">68</a>]. It may be infrequent or occur with the least movement of the head or neck. Although most frequently encountered in MS, this symptom also can be seen with other lesions of the cervical cord, including tumors, cervical disc herniation, postradiation myelopathy, and following trauma. </p><p class="headingAnchor" id="H3922656389"><span class="h2">Sensory symptoms</span><span class="headingEndMark"> — </span>Sensory symptoms are the most common initial feature of MS  (<a class="graphic graphic_table graphicRef61789" href="/z/d/graphic/61789.html" rel="external">table 3</a>) and are present in almost every patient at some time during the course of disease. The sensory features can reflect spinothalamic, posterior column, or dorsal root entry zone lesions. Symptoms are commonly described as numbness, tingling, pins-and-needles, tightness, coldness, or swelling of the limbs or trunk. Radicular pains also can be present, particularly in the low thoracic and abdominal regions. An intense itching sensation, especially in the cervical dermatomes and usually unilateral, is suggestive of MS.</p><p>The most common sensory abnormalities on clinical examination include:</p><p class="bulletIndent1"><span class="glyph">●</span>Varying degrees of impairment of vibration and joint position sense</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased pain and light touch perception in a distal distribution in the four extremities</p><p class="bulletIndent1"><span class="glyph">●</span>Patchy areas of reduced pain and light touch perception in the limbs and trunk</p><p></p><p>Upon testing sensation with a sharp object such as a pin, patients frequently report that the sharp feeling is increased, or that it feels like a mild electric shock, or that the stimulus spreads in a ripple fashion from the point at which it is applied. A bilateral sensory level is more common than a hemisensory syndrome. The latter is termed a Brown-Séquard syndrome when it is coupled with contralateral weakness. (See  <a class="medical medical_review" href="/z/d/html/5110.html" rel="external">"Anatomy and localization of spinal cord disorders", section on 'Brown-Sequard (hemicord) syndrome'</a>.)</p><p>Impairment of facial sensation, subjective or objective, is a relatively common finding in MS. Trigeminal neuralgia (see  <a class="medical medical_review" href="/z/d/html/5283.html" rel="external">"Trigeminal neuralgia"</a>) in a young adult may be an early sign of MS. Facial myokymia, a fine undulating wave-like facial twitching, and hemifacial spasm also can be due to MS, but other causes of a focal brainstem lesion must be excluded. Unilateral facial paresis can occur, and taste sensation is sometimes affected [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H2954042241"><span class="h2">Sexual dysfunction</span><span class="headingEndMark"> — </span>Sexual dysfunction is common in patients with MS [<a href="#rid70">70</a>]. About 50 percent of patients become completely sexually inactive secondary to their disease, and an additional 20 percent become sexually less active [<a href="#rid8">8</a>]. In men with MS, the most common complaints are reduced libido, erectile impotence, the disappearance of early morning erection, premature ejaculation, orgasmic dysfunction, and reduced penile sensation. In women with MS, the most common complaints are reduced libido, difficulties in achieving orgasm, decreased vaginal lubrication, decreased vaginal sensation, and dyspareunia [<a href="#rid71">71</a>].</p><p>Sexual dysfunction can be the result of multiple problems, including the direct effects of lesions of the motor and sensory pathways within the spinal cord and psychological factors involved with self-image, self-esteem, and fear of rejection from the sexual partner [<a href="#rid71">71</a>]. Mechanical problems created by spasticity, paraparesis, and incontinence further aggravate the problem. </p><p>Sphincter and sexual dysfunction associated with MS are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Sexual dysfunction'</a> and  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Bladder dysfunction'</a>.)</p><p class="headingAnchor" id="H2007162043"><span class="h2">Sleep disorders</span><span class="headingEndMark"> — </span>A 2015 systematic review identified 18 studies evaluating the prevalence of sleep disorders in subjects with MS [<a href="#rid72">72</a>]. Most of the studies were based in MS clinics; none were population-based. Studies of sleep quality or insomnia were not reviewed because of variable definitions of these conditions. The main sleep disorders and their prevalence ranges were the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Restless legs syndrome, 14 to 58 percent (12 studies)</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive sleep apnea, 7 to 58 percent (5 studies)</p><p class="bulletIndent1"><span class="glyph">●</span>Periodic limb movements of sleep, 36 percent (1 study)</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid eye movement sleep behavior disorder, 2 to 3 percent (2 studies)</p><p class="bulletIndent1"><span class="glyph">●</span>Narcolepsy, 0 to 2 percent (2 studies)</p><p></p><p>Given the lack of population-based studies, the true incidence and prevalence of these disorders in the MS population is unknown [<a href="#rid72">72</a>].</p><p>A substantial proportion of patients with MS suffer from insomnia with difficulty initiating and maintaining sleep. Limited data suggest that the prevalence of insomnia in MS is as high as 40 percent, or several times higher than the prevalence in the general population [<a href="#rid73">73-76</a>]. Factors contributing to insomnia include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Pain syndromes (eg, muscle spasms, Lhermitte sign, and trigeminal neuralgia)</p><p class="bulletIndent1"><span class="glyph">●</span>Restless legs syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Nocturia</p><p class="bulletIndent1"><span class="glyph">●</span>Medication side effects, particularly stimulant medications used to treat fatigue</p><p class="bulletIndent1"><span class="glyph">●</span>Psychiatric syndromes (eg, anxiety and depression)</p><p></p><p>The prevalence of restless legs syndrome in patients with MS is estimated to be fourfold higher compared with the general population (19 versus 4.2 percent, respectively) [<a href="#rid77">77</a>]. Therefore, patients with MS who complain of insomnia and excessive daytime somnolence should be evaluated for restless legs syndrome [<a href="#rid78">78</a>]; the diagnosis is made by history. Patients with MS and restless legs syndrome may have more cervical cord lesions than do those patients with MS who do not have restless legs syndrome, as revealed by conventional and non-conventional MRI techniques [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/z/d/html/4892.html" rel="external">"Clinical features and diagnosis of restless legs syndrome and periodic limb movement disorder in adults"</a>.)</p><p>Nocturia and pain frequently interrupt sleep in patients with MS. Nocturia affects as many as 70 to 80 percent of patients with MS [<a href="#rid80">80</a>]. Pain can disrupt sleep, causing daytime somnolence and worsening fatigue as well as reducing pain threshold.</p><p class="headingAnchor" id="H1468091132"><span class="h2">Vertigo</span><span class="headingEndMark"> — </span>Vertigo is a reported symptom in 30 to 50 percent of patients with MS. One retrospective study found that the most common cause of vertigo in patients with MS was benign positional paroxysmal vertigo [<a href="#rid81">81</a>]. However, vertigo is often directly related to the development of demyelinating plaques in the vestibular pathways such as the medullary tegmentum and the root entry zone of the eighth cranial nerve in the pontomedullary junction, or to other demyelinating brain stem lesions. In such cases, vertigo may be associated with symptoms reflecting dysfunction of adjacent cranial nerves such as hyper- or hypoacusis, facial numbness, and diplopia. </p><p>Vertigo from a demyelinating lesion tends to last for a longer duration (hours to days) and typically does not have positional triggers when compared with benign positional paroxysmal vertigo (BPPV), which is a common misdiagnosis in this setting. (See  <a class="medical medical_review" href="/z/d/html/5098.html" rel="external">"Benign paroxysmal positional vertigo"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Visual symptoms</span><span class="headingEndMark"> — </span>Optic neuritis is the most common type of involvement of the visual pathways with MS (see  <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">"Optic neuritis: Pathophysiology, clinical features, and diagnosis"</a>). Optic neuritis usually presents as acute or subacute unilateral eye pain that is accentuated by ocular movements [<a href="#rid82">82</a>]. This is followed by a variable degree of visual loss (scotoma) affecting mainly central vision. Bilateral simultaneous optic neuritis is rare in MS; its occurrence in isolation may suggest another diagnosis such as Leber hereditary optic atrophy, toxic optic neuropathy, or neuromyelitis optica (NMO) spectrum disease. When bilateral optic neuritis occurs in patients with MS, the impairment begins asymmetrically and is usually more severe in one eye.</p><p>Physical examination of patients with optic neuritis reveals a relative afferent pupillary defect (Marcus-Gunn pupil), which is evaluated with the swinging flashlight test  (<a class="graphic graphic_figure graphicRef71937" href="/z/d/graphic/71937.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef102285" href="/z/d/graphic/102285.html" rel="external">picture 1</a>). When the acute optic neuritis lesion involves the head of the optic nerve, disc edema may be observed on fundus examination, a finding more common in children than in adults. Most often the lesion of the optic nerve is retrobulbar, and in the acute stage fundus examination is normal. Later the optic disc becomes pale as a result of axonal loss and resultant gliosis. This pallor predominates in the temporal segment of the disc (temporal pallor).</p><p>Ninety percent of patients regain normal vision over a period of two to six months after an acute episode of optic neuritis. Desaturation of bright colors, particularly red, is often reported by recovered patients; some also report a mild nonspecific dimming. (See  <a class="medical medical_review" href="/z/d/html/5252.html" rel="external">"Optic neuritis: Prognosis and treatment", section on 'Prognosis'</a>.)</p><p>Patients with MS might also report an interesting visual phenomenon called the Pulfrich phenomenon, which is an illusory perception that an object moving linearly along a two-dimensional plane appears to instead follow an elliptical three-dimensional trajectory [<a href="#rid67">67,83</a>]. This phenomenon is a consequence of inter-eye asymmetry in the timing of visual object identification in the visual cortex, with optic neuritis as a common etiology. </p><p>Bitemporal hemianopia is rare in MS and, if present, should raise the suspicion of a mass lesion compressing the visual pathways. Homonymous field defects are uncommon but can be seen in MS due to involvement of the optic radiations.</p><p class="headingAnchor" id="H793790490"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Multiple sclerosis is a clinical diagnosis. The core requirement of the diagnosis is the demonstration of central nervous system lesion dissemination in time and space. The diagnosis of MS is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults"</a>.)</p><p class="headingAnchor" id="H10129013"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15821.html" rel="external">"Patient education: Multiple sclerosis in adults (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H190608281"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – Most patients with multiple sclerosis (MS) have relapsing-remitting disease, which often begins in a young adult with a clinically isolated syndrome suggestive of MS such as optic neuritis, long tract symptoms/signs, a brainstem syndrome (eg, internuclear ophthalmoplegia), or a spinal cord syndrome (eg, transverse myelitis). (See  <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults", section on 'Clinically isolated syndrome'</a>.)</p><p></p><p class="bulletIndent1">The typical patient with relapsing-remitting MS presents as a young adult with two or more clinically distinct episodes of central nervous system dysfunction with at least partial resolution. A minority of adult patients have the primary progressive form of MS, which presents with gradual accumulation of disability from the onset. (See <a class="local">'Presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms and signs</strong> – There are no clinical findings that are unique to MS, but some are highly characteristic of the disease  (<a class="graphic graphic_table graphicRef63940" href="/z/d/graphic/63940.html" rel="external">table 2</a>). Common manifestations of MS  (<a class="graphic graphic_table graphicRef61789" href="/z/d/graphic/61789.html" rel="external">table 3</a>) include the following (see <a class="local">'Clinical symptoms and signs'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bowel and bladder dysfunction (see <a class="local">'Bowel and bladder dysfunction'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive impairment (see <a class="local">'Cognitive impairment'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fatigue (see <a class="local">'Fatigue'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gait disturbance and balance problems (see <a class="local">'Incoordination'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heat sensitivity (see <a class="local">'Heat sensitivity'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Motor symptoms (see <a class="local">'Motor symptoms'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pain (see <a class="local">'Pain'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Paroxysmal symptoms (see <a class="local">'Paroxysmal symptoms'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sensory symptoms (see <a class="local">'Sensory symptoms'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sexual dysfunction (see <a class="local">'Sexual dysfunction'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vertigo (see <a class="local">'Vertigo'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Visual disturbances (see <a class="local">'Eye movement abnormalities'</a> above and <a class="local">'Visual symptoms'</a> above)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rice CM, Cottrell D, Wilkins A, Scolding NJ. Primary progressive multiple sclerosis: progress and challenges. J Neurol Neurosurg Psychiatry 2013; 84:1100.</a></li><li><a class="nounderline abstract_t">Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17:162.</a></li><li><a class="nounderline abstract_t">Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002; 6:1.</a></li><li><a class="nounderline abstract_t">DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 2003; 63:153.</a></li><li><a class="nounderline abstract_t">Wintner A, Kim MM, Bechis SK, Kreydin EI. Voiding Dysfunction in Multiple Sclerosis. Semin Neurol 2016; 36:34.</a></li><li><a class="nounderline abstract_t">Yang CC. Bladder management in multiple sclerosis. Phys Med Rehabil Clin N Am 2013; 24:673.</a></li><li><a class="nounderline abstract_t">Frohman TC, Castro W, Shah A, et al. Symptomatic therapy in multiple sclerosis. Ther Adv Neurol Disord 2011; 4:83.</a></li><li><a class="nounderline abstract_t">Hennessey A, Robertson NP, Swingler R, Compston DA. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 1999; 246:1027.</a></li><li><a class="nounderline abstract_t">Staff NP, Lucchinetti CF, Keegan BM. Multiple sclerosis with predominant, severe cognitive impairment. Arch Neurol 2009; 66:1139.</a></li><li><a class="nounderline abstract_t">Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008; 7:1139.</a></li><li><a class="nounderline abstract_t">Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74:443.</a></li><li><a class="nounderline abstract_t">Deloire MS, Salort E, Bonnet M, et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:519.</a></li><li><a class="nounderline abstract_t">Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41:685.</a></li><li><a class="nounderline abstract_t">Huijbregts SC, Kalkers NF, de Sonneville LM, et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 2004; 63:335.</a></li><li><a class="nounderline abstract_t">Ruet A, Deloire M, Charré-Morin J, et al. Cognitive impairment differs between primary progressive and relapsing-remitting MS. Neurology 2013; 80:1501.</a></li><li><a class="nounderline abstract_t">Franklin GM, Heaton RK, Nelson LM, et al. Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. Neurology 1988; 38:1826.</a></li><li><a class="nounderline abstract_t">Hohol MJ, Guttmann CR, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 1997; 54:1018.</a></li><li><a class="nounderline abstract_t">Rao SM, Leo GJ, Haughton VM, et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989; 39:161.</a></li><li><a class="nounderline abstract_t">Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66:1144.</a></li><li><a class="nounderline abstract_t">Amato MP, Bartolozzi ML, Zipoli V, et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 2004; 63:89.</a></li><li><a class="nounderline abstract_t">Sanfilipo MP, Benedict RH, Weinstock-Guttman B, Bakshi R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 2006; 66:685.</a></li><li><a class="nounderline abstract_t">Calabrese M, Rinaldi F, Mattisi I, et al. Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology 2010; 74:321.</a></li><li><a class="nounderline abstract_t">Filippi M, Rocca MA, Benedict RH, et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 2010; 75:2121.</a></li><li><a class="nounderline abstract_t">Mesaros S, Rocca MA, Kacar K, et al. Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. Neurology 2012; 78:969.</a></li><li><a class="nounderline abstract_t">Gilchrist AC, Creed FH. Depression, cognitive impairment and social stress in multiple sclerosis. J Psychosom Res 1994; 38:193.</a></li><li><a class="nounderline abstract_t">Mohr DC, Goodkin DE, Gatto N, Van der Wende J. Depression, coping and level of neurological impairment in multiple sclerosis. Mult Scler 1997; 3:254.</a></li><li><a class="nounderline abstract_t">Arnett PA, Higginson CI, Randolph JJ. Depression in multiple sclerosis: relationship to planning ability. J Int Neuropsychol Soc 2001; 7:665.</a></li><li><a class="nounderline abstract_t">Arnett PA, Higginson CI, Voss WD, et al. Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning. Neuropsychology 1999; 13:434.</a></li><li><a class="nounderline abstract_t">Thornton AE, Raz N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychology 1997; 11:357.</a></li><li><a class="nounderline abstract_t">Arnett PA, Higginson CI, Voss WD, et al. Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology 1999; 13:546.</a></li><li><a class="nounderline abstract_t">Zagzag D, Miller DC, Kleinman GM, et al. Demyelinating disease versus tumor in surgical neuropathology. Clues to a correct pathological diagnosis. Am J Surg Pathol 1993; 17:537.</a></li><li><a class="nounderline abstract_t">Rao SM, Reingold SC, Ron MA, et al. Workshop on Neurobehavioral Disorders in Multiple Sclerosis. Diagnosis, underlying disease, natural history, and therapeutic intervention, Bergamo, Italy, June 25-27, 1992. Arch Neurol 1993; 50:658.</a></li><li><a class="nounderline abstract_t">Patten SB, Beck CA, Williams JV, et al. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003; 61:1524.</a></li><li><a class="nounderline abstract_t">Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41:1193.</a></li><li><a class="nounderline abstract_t">Stenager EN, Stenager E. Suicide and patients with neurologic diseases. Methodologic problems. Arch Neurol 1992; 49:1296.</a></li><li><a class="nounderline abstract_t">Fredrikson S, Cheng Q, Jiang GX, Wasserman D. Elevated suicide risk among patients with multiple sclerosis in Sweden. Neuroepidemiology 2003; 22:146.</a></li><li><a class="nounderline abstract_t">Brønnum-Hansen H, Stenager E, Nylev Stenager E, Koch-Henriksen N. Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:1457.</a></li><li><a class="nounderline abstract_t">Sumelahti ML, Tienari PJ, Wikström J, et al. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult Scler 2002; 8:350.</a></li><li><a class="nounderline abstract_t">Brønnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004; 127:844.</a></li><li><a class="nounderline abstract_t">Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502.</a></li><li><a class="nounderline abstract_t">Patten SB, Metz LM, SPECTRIMS Study Group. Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 2002; 59:744.</a></li><li><a class="nounderline abstract_t">Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352:1491.</a></li><li><a class="nounderline abstract_t">Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39:285.</a></li><li><a class="nounderline abstract_t">Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352:1498.</a></li><li><a class="nounderline abstract_t">Koch M, Uyttenboogaart M, Polman S, De Keyser J. Seizures in multiple sclerosis. Epilepsia 2008; 49:948.</a></li><li><a class="nounderline abstract_t">Barnes D, McDonald WI. The ocular manifestations of multiple sclerosis. 2. Abnormalities of eye movements. J Neurol Neurosurg Psychiatry 1992; 55:863.</a></li><li><a class="nounderline abstract_t">Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111.</a></li><li><a class="nounderline abstract_t">Aschoff JC, Conrad B, Kornhuber HH. Acquired pendular nystagmus with oscillopsia in multiple sclerosis: a sign of cerebellar nuclei disease. J Neurol Neurosurg Psychiatry 1974; 37:570.</a></li><li><a class="nounderline abstract_t">Barton JJ, Cox TA. Acquired pendular nystagmus in multiple sclerosis: clinical observations and the role of optic neuropathy. J Neurol Neurosurg Psychiatry 1993; 56:262.</a></li><li><a class="nounderline abstract_t">Gresty MA, Ell JJ, Findley LJ. Acquired pendular nystagmus: its characteristics, localising value and pathophysiology. J Neurol Neurosurg Psychiatry 1982; 45:431.</a></li><li><a class="nounderline abstract_t">Attarian HP, Brown KM, Duntley SP, et al. The relationship of sleep disturbances and fatigue in multiple sclerosis. Arch Neurol 2004; 61:525.</a></li><li><a class="nounderline abstract_t">Čarnická Z, Kollár B, Šiarnik P, et al. Sleep disorders in patients with multiple sclerosis. J Clin Sleep Med 2015; 11:553.</a></li><li><a class="nounderline abstract_t">Tartaglia MC, Narayanan S, Francis SJ, et al. The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol 2004; 61:201.</a></li><li><a class="nounderline abstract_t">Braley TJ, Segal BM, Chervin RD. Hypnotic use and fatigue in multiple sclerosis. Sleep Med 2015; 16:131.</a></li><li><a class="nounderline abstract_t">Selhorst JB, Saul RF. Uhthoff and his symptom. J Neuroophthalmol 1995; 15:63.</a></li><li><a class="nounderline abstract_t">Frohman TC, Davis SL, Beh S, et al. Uhthoff's phenomena in MS--clinical features and pathophysiology. Nat Rev Neurol 2013; 9:535.</a></li><li><a class="nounderline abstract_t">Syndulko K, Jafari M, Woldanski A, et al. Effects of temperature in multiple sclerosis: A review of the literature. Neurorehabil Neural Repair 1996; 10:23.</a></li><li><a class="nounderline abstract_t">Davis SL, Wilson TE, White AT, Frohman EM. Thermoregulation in multiple sclerosis. J Appl Physiol (1985) 2010; 109:1531.</a></li><li><a class="nounderline abstract_t">Humm AM, Beer S, Kool J, et al. Quantification of Uhthoff's phenomenon in multiple sclerosis: a magnetic stimulation study. Clin Neurophysiol 2004; 115:2493.</a></li><li><a class="nounderline abstract_t">Rinker JR 2nd, Salter AR, Walker H, et al. Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey. BMJ Open 2015; 5:e006714.</a></li><li><a class="nounderline abstract_t">Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10:589.</a></li><li><a class="nounderline abstract_t">Thompson AJ, Jarrett L, Lockley L, et al. Clinical management of spasticity. J Neurol Neurosurg Psychiatry 2005; 76:459.</a></li><li><a class="nounderline abstract_t">Trompetto C, Marinelli L, Mori L, et al. Pathophysiology of spasticity: implications for neurorehabilitation. Biomed Res Int 2014; 2014:354906.</a></li><li><a class="nounderline abstract_t">Drulovic J, Basic-Kes V, Grgic S, et al. The Prevalence of Pain in Adults with Multiple Sclerosis: A Multicenter Cross-Sectional Survey. Pain Med 2015; 16:1597.</a></li><li><a class="nounderline abstract_t">Foley PL, Vesterinen HM, Laird BJ, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain 2013; 154:632.</a></li><li><a class="nounderline abstract_t">Kahraman T, Özdoğar AT, Ertekin Ö, Özakbaş S. Frequency, type, distribution of pain and related factors in persons with multiple sclerosis. Mult Scler Relat Disord 2019; 28:221.</a></li><li><a class="nounderline abstract_t">Rae-Grant AD. Unusual symptoms and syndromes in multiple sclerosis. Continuum (Minneap Minn) 2013; 19:992.</a></li><li><a class="nounderline abstract_t">Kanchandani R, Howe JG. Lhermitte's sign in multiple sclerosis: a clinical survey and review of the literature. J Neurol Neurosurg Psychiatry 1982; 45:308.</a></li><li class="breakAll">McGraw C, Krieger S, Wong J, Fabian M. The food critic who couldn't taste and 6 other cases of dysgeusia in multiple sclerosis. Neurology 2012; 78(Meeting Abstracts 1):P06.178. www.neurology.org/cgi/content/meeting_abstract/78/1_MeetingAbstracts/P06.178 (Accessed on March 10, 2015).</li><li><a class="nounderline abstract_t">Lew-Starowicz M, Gianotten WL. Sexual dysfunction in patients with multiple sclerosis. Handb Clin Neurol 2015; 130:357.</a></li><li><a class="nounderline abstract_t">Zivadinov R, Zorzon M, Bosco A, et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 1999; 5:428.</a></li><li><a class="nounderline abstract_t">Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mult Scler 2015; 21:342.</a></li><li><a class="nounderline abstract_t">Tachibana N, Howard RS, Hirsch NP, et al. Sleep problems in multiple sclerosis. Eur Neurol 1994; 34:320.</a></li><li><a class="nounderline abstract_t">Brass SD, Duquette P, Proulx-Therrien J, Auerbach S. Sleep disorders in patients with multiple sclerosis. Sleep Med Rev 2010; 14:121.</a></li><li><a class="nounderline abstract_t">Stanton BR, Barnes F, Silber E. Sleep and fatigue in multiple sclerosis. Mult Scler 2006; 12:481.</a></li><li><a class="nounderline abstract_t">Caminero A, Bartolomé M. Sleep disturbances in multiple sclerosis. J Neurol Sci 2011; 309:86.</a></li><li><a class="nounderline abstract_t">Schürks M, Bussfeld P. Multiple sclerosis and restless legs syndrome: a systematic review and meta-analysis. Eur J Neurol 2013; 20:605.</a></li><li><a class="nounderline abstract_t">Trojan DA, Da Costa D, Bar-Or A, et al. Sleep abnormalities in multiple sclerosis patients. Mult Scler 2008; 14:S160.</a></li><li><a class="nounderline abstract_t">Manconi M, Rocca MA, Ferini-Strambi L, et al. Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. Mult Scler 2008; 14:86.</a></li><li><a class="nounderline abstract_t">Amarenco G, Kerdraon J, Denys P. [Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases]. Rev Neurol (Paris) 1995; 151:722.</a></li><li><a class="nounderline abstract_t">Frohman EM, Zhang H, Dewey RB, et al. Vertigo in MS: utility of positional and particle repositioning maneuvers. Neurology 2000; 55:1566.</a></li><li><a class="nounderline abstract_t">Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med 2006; 354:1273.</a></li><li><a class="nounderline abstract_t">Sobhanian MJ, Agarwal R, Meltzer E, et al. Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon. J Neurol Sci 2018; 387:60.</a></li></ol></div><div id="topicVersionRevision">Topic 1689 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23418213" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Primary progressive multiple sclerosis: progress and challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29275977" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12022938" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12515563" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26866494" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Voiding Dysfunction in Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24314685" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bladder management in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21694806" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Symptomatic therapy in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631634" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Urinary, faecal and sexual dysfunction in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19752304" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Multiple sclerosis with predominant, severe cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19007738" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cognitive impairment in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12640060" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cognitive impairment in probable multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15774439" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2027484" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277630" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23516324" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cognitive impairment differs between primary progressive and relapsing-remitting MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3194059" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9267977" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2915783" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19752305" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249616" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534104" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20101038" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Widespread cortical thinning characterizes patients with MS with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21135387" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The contribution of MRI in assessing cognitive impairment in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22377806" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8027959" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Depression, cognitive impairment and social stress in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9372510" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Depression, coping and level of neurological impairment in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11575588" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Depression in multiple sclerosis: relationship to planning ability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10447304" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9223140" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Memory impairment in multiple sclerosis: a quantitative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10527063" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Depression in multiple sclerosis: relationship to working memory capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8333553" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Demyelinating disease versus tumor in surgical neuropathology. Clues to a correct pathological diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8099276" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Workshop on Neurobehavioral Disorders in Multiple Sclerosis. Diagnosis, underlying disease, natural history, and therapeutic intervention, Bergamo, Italy, June 25-27, 1992.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14663036" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Major depression in multiple sclerosis: a population-based perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1866003" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cause of death in patients attending multiple sclerosis clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1449409" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Suicide and patients with neurologic diseases. Methodologic problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12629281" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Elevated suicide risk among patients with multiple sclerosis in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170097" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Suicide among Danes with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12166507" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Survival of multiple sclerosis in Finland between 1964 and 1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14960501" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Trends in survival and cause of death in Danish patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18970977" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12221168" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820296" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602746" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820297" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18336559" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Seizures in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1431948" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The ocular manifestations of multiple sclerosis. 2. Abnormalities of eye movements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15664543" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The neuro-ophthalmology of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4836752" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acquired pendular nystagmus with oscillopsia in multiple sclerosis: a sign of cerebellar nuclei disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8459242" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acquired pendular nystagmus in multiple sclerosis: clinical observations and the role of optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7086456" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acquired pendular nystagmus: its characteristics, localising value and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15096400" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The relationship of sleep disturbances and fatigue in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25700869" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sleep disorders in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14967766" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The relationship between diffuse axonal damage and fatigue in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25454981" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hypnotic use and fatigue in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7550931" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Uhthoff and his symptom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23732530" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Uhthoff's phenomena in MS--clinical features and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effects of temperature in multiple sclerosis: A review of the literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20671034" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Thermoregulation in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15465437" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Quantification of Uhthoff's phenomenon in multiple sclerosis: a magnetic stimulation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25573524" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15471378" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prevalence and treatment of spasticity reported by multiple sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15774425" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical management of spasticity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25530960" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pathophysiology of spasticity: implications for neurorehabilitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26087108" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The Prevalence of Pain in Adults with Multiple Sclerosis: A Multicenter Cross-Sectional Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23318126" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30623861" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Frequency, type, distribution of pain and related factors in persons with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23917097" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Unusual symptoms and syndromes in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7077340" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Lhermitte's sign in multiple sclerosis: a clinical survey and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7077340" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Lhermitte's sign in multiple sclerosis: a clinical survey and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26003254" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Sexual dysfunction in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10618700" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sexual dysfunction in multiple sclerosis: II. Correlation analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25533301" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7851452" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sleep problems in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19879170" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Sleep disorders in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16900762" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Sleep and fatigue in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21813138" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Sleep disturbances in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23078359" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Multiple sclerosis and restless legs syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Sleep abnormalities in multiple sclerosis patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942519" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8787103" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : [Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11094117" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Vertigo in MS: utility of positional and particle repositioning maneuvers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16554529" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical practice. Optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29571874" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
